Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3003  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
  » Next article
  » Previous article 
  » Table of Contents
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,987 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 »  Introduction
 »  Materials and Me...
 »  Results
 »  Discussion
 »  Acknowledgments
 »  References
 »  Article Figures

 Article Access Statistics
    PDF Downloaded144    
    Comments [Add]    
    Cited by others 20    

Recommend this journal


Year : 2009  |  Volume : 57  |  Issue : 6  |  Page : 722-728

Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats

1 Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing - 400 016, China
2 Medical Laboratory, Chongqing Medical University, Chongqing - 400 016, China

Date of Acceptance02-Jul-2009
Date of Web Publication30-Jan-2010

Correspondence Address:
Z B Liao
Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing- 400 016
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.59466

Rights and Permissions

 » Abstract 

Background : Traumatic brain injury (TBI) is an important cause of adult mortality and morbidity. Erythropoietin (Epo) has been shown to promote the viability of cerebral cells by upregulating Bcl-2 gene; however, Epo may exert its antiapoptotic effect via the differential regulation of the expression of genes involved in the apoptotic process. Aim : The present study examined the neuroprotective effect of Epo as a survival factor through the regulation of the Bax. Materials and Methods : Wistar rats were randomly divided into three groups: Recombinant human EPO treated (rhEPO) TBI, vehicle-treated TBI, and sham-operated. Traumatic brain injury was induced by the Feeney free-falling model. Rats were killed 5, 12, 24, 72, 120, or 168 h after TBI. Regulation of Bcl-2 was detected by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and immunofluorescence. Results : Bax mRNA and protein levels were lower in the rhEPO)-treated rat brains than in the vehicle-treated rat brains. Induction of Bax expression peaked at 24 h and remained stable for 72-120 h in vehicle-treated rat brains, whereas induction of Bax expression was only slightly elevated in rhEPO-treated rat brains. The number of TdT-mediated dUTP Nick-End Labeling(TUNEL)-positive cells in the rhEPO-treated rat brains was far fewer than in the vehicle-treated rat brains. Conclusions : Epo exerts neuroprotective effect against traumatic brain injury via reducing Bax gene expression involved in inhibiting TBI-induced neuronal cell death.

Keywords: Bax, cell death, rhEPO, traumatic brain injury

How to cite this article:
Liao Z B, Jiang G Y, Tang Z H, Zhi X G, Sun X C, Tang W Y, Wu M J. Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats. Neurol India 2009;57:722-8

How to cite this URL:
Liao Z B, Jiang G Y, Tang Z H, Zhi X G, Sun X C, Tang W Y, Wu M J. Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats. Neurol India [serial online] 2009 [cited 2023 Nov 29];57:722-8. Available from:

 » Introduction Top

The high incidence of adverse outcomes following traumatic brain injury (TBI) has been attributed to a large extent to the secondary mechanisms of neuronal cell death. [1],[2] These mechanisms include induction of neuronal cell death and complement-mediated neuronal cell lysis. [3],[4],[5],[6],[7] A number of studies have demonstrated that TBI-induced neuronal cell death is crucial for secondary injury, and anti-apoptotic effects may account in large part for the protective effects. [8],[9] Neuronal and glial cell death contribute to the overall pathology of TBI in both humans and animals. In both experimental head-injury models and human TBI, apoptotic cells and degenerating cells exhibiting classic necrotic morphology have been observed. [10],[11]

Neuroprotective strategies for prevention of the neuropathological sequelae of TBI have largely failed in translation to clinical treatment. [12],[13],[14] Thus, there is a need for further understanding of the molecular mechanisms of the drugs which inhibit neuronal cell death in the injured brain. [15] Erythropoietin (EPO) is a cytokine that was originally identified as the major regulator of erythroid precursor cells. [16],[17],[18] However, increasing evidence suggests that EPO has broader functions independent of its effects on erythropoiesis. EPO has a neuroprotective effect in animal models of global and focal cerebral ischemia, as well as in adult rodent models of spinal ischemia, [19] Although the exact mechanism of neuroprotection is unknown, EPO likely promotes signaling cascades involved in cell survival and/or upregulation of antiapoptotic proteins. [20] In our earlier study we have shown enhanced erythropoietin- receptor expression for almost a week after TBI, where as EPO was slightly elevated, that too in the first 72 h only. [21] EPO administration protects neurons by enhancing Bcl-2 expression and thus inhibits TBI-induced neuronal cell death. However, EPO may exert its antiapoptotic effect via the differential regulation of the expression of genes involved in the apoptotic process. In the present study we explored the regulation of Bax gene after TBI, as well as the anti-apoptotic effects of recombinant human EPO (rhEPO) treatment.

 » Materials and Methods Top

Animal experiments

Wistar rats (180-210 g, Chongqing Medical University, China) were housed under 12-h periods of light and darkness with free access to food and water. All procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996). The number of animals used and their suffering were minimized. TBI (1000 g-cm) was induced in anesthetized rats using the weight-drop contusion model as described. [9],[10] Briefly, 120 rats were anesthetized using sodium pentobarbital (60 mg/kg i.p.) and underwent a craniotomy, in which a circular region of the skull (3.0 mm diameter, cantered 2.3 mm caudal and 2.3 mm lateral to bregma) was removed over the right somatosensory cortex. A weight-drop device was placed stereotactically over the dura and adjusted to stop an impact transducer (foot plate) at a depth of 25 mm below the dura. Then, a 40-g weight was dropped from 25 cm above the dura, through a guide role, onto the foot plate. Body temperature was also monitored during surgery with a rectal probe and maintained in the range of 36.5-37.5°C with a heating pad. After the injury, the scalp was sutured. No trauma was induced in the sham-operated group. Rats were killed 5, 12, 24, 72, 120, and 168 h after TBI.

Animal groups

Rats were randomly divided into three groups: Recombinant human EPO (rhEPO) treated TBI (n = 60), vehicle-treated TBI (n = 60), and sham-operated (n = 10). EPO (5,000 IU/kg; 3cbio, Shengyang province, China) or vehicle (2 mL containing 2.50 mg human serum albumin, 5.84 mg sodium chloride, 1.164 mg sodium phosphate monobasic dehydrate, and 2.225 mg sodium phosphate dibasic dehydrate per mL) was administered intraperitoneally once a day for seven days after TBI. Doses of EPO were selected based on previous studies. [11] Tissue samples were collected from ten EPO- and ten vehicle-treated rats at 5, 12, 24, 72, 120, and 168 h after TBI. The sham-operated tissue samples were collected 168 h after TBI.

Tissue processing

Rats were killed by decapitation and the brains were rapidly dissected, frozen on liquid nitrogen, and stored at -80°C for biochemical analysis for T dT-mediated d U TP N ick- E nd L abeling (TUNEL) staining and immunofluorescence, Rats were deeply anesthetized with sodium pentobarbital (60 mg kg i.p.) and then transcardially perfused with 400 ml 4% paraformaldehyde and 100 ml 30% sucrose. Fixed brains were removed and stored at -80°C.


Brain tissues from the peritrauma cortex (surround the impact point from 1 cm to 1.5 cm) in rhEPO-treated TBI, vehicle-treated TBI, and sham-operated rats were rigorously homogenized. Total RNA from the peritrauma cortex tissue was isolated using the TRIzol method. For Bax RT-PCR amplification, the forward and reverse primers were 5'-CTCAGAAGGAATTGATGTCG-3'and 5'-TCACGCCAACCCTCCACCAC-3'respectively, yielding a145-bp PCR product. β-actin was used as an internal standard; the forward and reverse primers were 5'-ATGCATCCTGCACCACCAAC-3'and 5'- TGGAGAAACCTGCCAAGTAT-3'respectively, yielding a 410-bp PCR product. The reaction was maintained at 42°C for 60 min, then at 92°C for 5 min before 35 cycles of: 94°C for 30 s, 53°C for 30 s, and 72°C for 60 s, followed by 72°C for 10 min. PCR products were electrophoresed on a 1.5% agarose gel and stained with ethidium bromide (2 µg/mL).

Western blotting

Brain tissues from the peritrauma cortex in rhEPO-treated TBI, vehicle-treated TBI, and sham- operated rats were rigorously homogenized and sonicated for 30 s in a lysis buffer as described. [6] Protein concentrations were determined and aliquots of 10 ug of the total proteins were separated by electrophoresis on SDS- polyacrylamide gels. Briefly, protein samples were separated by electrophoresis on an 8% polyacrylamide gel and electrotransferred to a nitrocellulose membrane. Non-specific binding sites were blocked by incubating overnight at 4°C in TBS containing 2% BSA and 0.1% Tween-20. Membranes were rinsed for 10 min in buffer (TBS containing 0.1% Tween-20) and then incubated with anti-Bax, anti-β-actin, (1:2000, Santa Cruz Biotechnology anti-rat) followed by anti-goat IgG horseradish peroxidase-conjugate (Santa Cruz Biotechnology). After rinsing with buffer, the immunocomplexes were visualized using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ) according to the manufacturer's instructions. Film signals were digitally scanned and then quantified using NIH Image software. β-actin was used as an internal control for all Western blots.


The peritrauma coronal sections of 10-um thickness were cut with a cryostat and mounted on slides. Cryosections were fixed in 1% paraformaldehyde in PBS and postfixed in a mixture of ethanol and acetic acid (2:1) at 20°C. Sections were washed in PBS and blocked by incubating in PBS containing 0.3% Triton X-100 and 2% BSA. Bax were localized with rabbit anti-Bax (Santa Cruz Biotechnology anti-rat) antibody at 1:2000. Bound primary antibodies were detected by incubation with fluorescein isothiocyanate (FITC)-coupled anti-rabbit IgG at 1:2500. Controls were performed by omission of the primary antibody. And the results of immunofluorescence controls were negative as no staining was observed in peritrauma cortex tissue. Sections were observed using the Aristoplan confocal laser-scanning microscope.

Neuronal cell death assay

The peritrauma coronal sections of 10-um thickness were cut with a cryostat. Neuronal cell death in the peritrauma cortex was examined with a commercial TUNEL assay kit (Santa Cruz Biotechnology) that enzymatically labels DNA strand breaks. Slides were incubated with blocking solution for 10 min at 20°C to eliminate endogenous peroxidases, followed by permeabilization solution for 2 min on ice. Then the TUNEL reaction (50 µL) was added and the slides were incubated in a humidified atmosphere in the dark for 1 h at 37°C. As a negative control, sections of the peritrauma cortex were used after the standard procedures, but labeled dUTP was omitted. Results are expressed as counting T dT-mediated d U TP N ick- E nd L abeling (TUNEL) labels apoptotic cells. Sections were observed using the Aristoplan confocal laser-scanning microscope. TUNEL labels , apoptotic cells were counted at five different fields in the inner border of the peritrauma cortex in five sections per rat over a microscopic field of 0.01 mm 2 , and averaged and expressed as cells/0.01 mm 2 . Five rat/group were analyzed by an observer blind to the experimental treatment (see below).

Image and data analysis

After capturing images with a digital camera, quantification of the results from Immunofluorescence, Western blotting and RT-PCR was performed with National Institutes of Health IMAGE 1.61 software. The total number of TUNEL-positive cells per image (cells/0.01 mm 2 , objective x40) was calculated by an observer blind to the experimental treatment. In each section, five peritrauma cortical areas outside labeled neurons were chosen randomly to obtain an average value for the subtraction of background by an observer blind to the experimental treatment. Statistical analysis was performed by ANOVA. All results were expressed as mean ± SD. A P value of <0.05 was considered to be statistically significant.

 » Results Top

Erythropoietin administration decreases Bax mRNA after traumatic brain injury

Basal levels of Bax mRNA were observed in sham-operated brain tissue [Figure 1]a (0.09 ± 0.021). In the vehicle- treated group, Bax mRNA was slightly upregulated at 5 h after TBI [0.11 ± 0.046;1.2-fold increase vs. sham, n = 5, P > 0.05; [Figure 1]b], significantly upregulated at 12 h [0.19 ± 0.048; n = 5, P < 0.05 vs. sham; [Figure 1]b], peaked at 24 h [0.37 ± 0.052, n = 5, P < 0.05 vs. sham; [Figure 1]b] and persisted at peak levels up to 168 h post-TBI. We also evaluated the effects of EPO administration on Bax mRNA level in TBI rats. In the rhEPO-treated group, Bax mRNA expression in the ipsilateral peritrauma cortex peaked at 72 h [0.29 ± 0.053, n = 5, P > 0.05 vs. sham; [Figure 1]b] and returned to near baseline by 120 h post-TBI [0.18 ± 0.056, n = 5, P > 0.05 vs. sham, [Figure 1]b].

Erythropoietin administration decreases the expression of Bax protein after traumatic brain injury

Next we determined whether EPO administration regulates TBI-induced Bax protein expression. Sham-operated samples expressed basal levels of Bax (0.23 ± 0.043). Relative to the sham group, Bax in the vehicle-treated TBI was elevated 1.3-fold [0.31 ± 0.046, n = 5, P > 0.05; [Figure 2]] at 5 h after TBI, reached a peak at 72 h [0.72 ± 0.051;3.1-fold, n = 5, P < 0.05; [Figure 2]], and was sustained to 168 h [0.61 ± 0.046;2.6-fold, n = 5, P < 0.05; [Figure 2]]. In the rhEPO-treated TBI group, Bax was increased by 1.1fold [0.27 ± 0.051; vs. sham, n = 5, P > 0.05; [Figure 2]] at 5 h post-TBI, 1.4-fold [0.34 ± 0.053, n = 5, P < 0.05; [Figure 2]] at 72 h, and 1.2-fold [0.27 ± 0.042, n = 5, P > 0.05; [Figure 2]] at 168 h. To determine the relative number of cells expressing Bax within the peritrauma cortex, immunofluorescence imaging was used. Bax was detected in many cells in the peritrauma cortex, many of which had morphological features characteristic of neurons. Strong Bax induction was observed throughout the peritrauma cortex from 24 h to 168 h post-TBI in the vehicle-treated group, whereas Bax expression was only observed transiently in the rhEPO-treated TBI group [Figure 3], consistent with Western blot analysis. Weak Bax immunoreactivity was also detected in the superficial cortex of sham-operated rats (data not shown).

Erythropoietin administration decreased the number of TdT-mediated dUTP Nick-End Labeling -positive neurons after traumatic brain injury

To evaluate the potential anti-apoptotic effects of EPO, we measured the number of apoptotic profiles by TUNEL staining. No TUNEL-positive cells were observed in the sham. TUNEL-positive cells were noted in the vehicle-treated TBI, predominantly in the peritrauma cortex [Figure 4]. The number of TUNEL-positive cells in the vehicle-treated TBI increased at 24 h [42 ± 5.59, n = 5, P < 0.05; [Figure 4]] post-TBI and peaked at 72 h [68 ± 7.51, n = 5, P < 0.05; [Figure 4]]. However, only scattered TUNEL-positive cells were observed in the rhEPO-treated TBI at 72 h [32 ± 5.48 n = 5, P < 0.05 vs. control; [Figure 4]]. Cell death was relatively constant over the time course in the rhEPO-treated TBI. In some TUNEL-positive cells, a condensed, clumped, or pyknotic nuclear pattern was observed.

 » Discussion Top

Based on the morphological criteria and the TUNEL method, cerebral cell loss was characterized by both cell necrosis and cell death These observations are in agreement with the previous studies. TBI initiates a complex cascade of events that eventually result in injury and subsequent necrosis and/or apoptotic death of cerebral cells. [22] We demonstrated that EPO inhibits apoptotic cell death in peritrauma cortex as determined by DNA fragmentation, confirming previous data which suggested that inhibition of cell death is one of the most potential protective mechanisms of EPO. [23],[24],[25] In rats subjected to TBI, systemic administration of EPO for seven days post trauma significantly reduced the number of TUNEL-positive cells in the peritrauma cortex compared to the vehicle-treated group, suggesting that EPO affords protection by inhibiting cell death.

Furthermore, in our earlier study, [21] our findings demonstrated that Bcl-2 protein is induced in peritrauma cortical cerebral cells in rhEPO-treated rats for 5 h post trauma and this effect was maintained up to 168 h, whereas in vehicle-treated rats the effect was maintained only for 72 h. Previous studies conducted in similar animal models of TBI have also shown that severe TBI leads to an increase in the Bax/Bcl-2 ratio suggesting that the fine balance between the activity of pro-apoptotic and anti-apoptotic Bcl-2 family members can determine cell survival and modulate the induction of cell death. [22],[23],[24],[25] In order to further clarify the anti-apoptotic mechanisms of EPO, we have also investigated the effect of TBI on the activation of Bax in the brain tissue with and without treatment of EPO. Bax is a cell-death gene implicated in the regulation of diverse biological phenomena, including cell death, cell survival and growth, cellular differentiation, hypoxia and ischemia. [26],[27],[28],[29],[30] The results in our study presented here demonstrates that TBI leads to activation of Bax, which suggests that it might be a marker of injury linked to the pathophysiology of TBI. [31] Induction of Bax expression peaked at 24 h and remained stable for 72-120 h in vehicle-treated TBI, whereas it was only slightly elevated in rhEPO-treated TBI. Roughly half of the cerebral cells in the peritrauma cortex of vehicle- treated TBI rats were Bax immunoreactive. Cerebral cells expressing Bax protein appeared to be peritrauma cortical neurons and glial cells. Administration of EPO also decreased the number of TUNEL-positive cells, suggesting that Bax plays an important role in regulating neuronal death and a complementary role as an inducible neuroprotective protein after TBI. i0 n vitro studies suggest that Bax possesses a key role in the phosphatidyl-inositol 3-kinase-Akt (PI3K-Akt) pathway that acts as a cell death signal in the regulation of cell death in neuronal or glial cells. [32],[33] It is already known from the recent literature that Bax plays a key role in the EPO-mediated cell death action in the nervous system. [34],[35],[36] It appears, therefore, that activation of Bax may serve a dual role in inhibiting or promoting cell death pathways in a cell type- and stimulus-dependent manner. [37]

Based on the information in the literature, recently, data provided by in vitro studies suggests that EPO-mediated protection against cell death may involve cross-talk between JAK2 [38] and NF-kB resulting in an early (within 24 h of TBI) activation of NF-kB signaling pathways. [39] However, an EPO-triggering activation through a specific signal transduction pathway and regulatory mechanisms, such as types of activated Bax homodimers could ensure the transient activation of the cell death factor and subsequently promote its beneficial role. [40],[41],[42],[43] This might be one of the potential mechanisms underlying the protective action of EPO, which functions independently or in combination with other intracellular signaling cascades. Alternative protective mechanisms that might be activated downstream from the EPO/EPOR system could include the regulation of mitogen-activated protein kinase (MAPK) and the (PI3K/Akt) system, as well as the increased expression of HSP70. [44],[45],[46] Evidence to support these hypotheses is derived from observations of in vitro and in vivo studies of TBI- induced injury in the central nervous system(CNS.) [47] Our data demonstrated that EPO administration offered significant protection against TBI via reducing Bax gene and upregulating Bcl-2 gene [48] expression involved in inhibiting TBI-induced neuronal cell death. However, the mechanism by which EPO protects peritrauma cortical cerebral cells against TBI is not fully elucidated. Improved understanding of EPO-mediated signaling cascade is needed in order to delineate the benefits of EPO therapy and incorporate its potential use into clinical practice in the future. Based on these findings, EPO treatment may represent a novel therapeutic approach due to its capacity to preserve CNS function and directly protect peritrauma cortex from traumatic brain injury in rats.

 » Acknowledgments Top

This research was supported by the National Natural Science Funds of China (30801182).

 » References Top

1.O9Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154-62.  Back to cited text no. 1      
2.Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ. Complement-dependent cell death and inflammatory gene changes in murine lupus cerebritis. J Immunol 2005;175:8312-9.   Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J Neurotrauma 2001;18:1295-311.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Ohlsson M, Bellander BM, Langmoen IA, Svensson M. Complement activation following optic nerve crush in the adult rat. J Neurotrauma 2003;20:895-904.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.McArthur DL, Chute DJ, Villablanca JP. Moderate and severe traumatic brain injury: Epidemiologic, imaging and neuropathologic perspectives. Brain Pathol 2004;14:185-94.   Back to cited text no. 5  [PUBMED]  [FULLTEXT]  
6.Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Bench-tobedside review: Cell death/programmed cell death triggered by traumatic brain injury. Crit Care 2005;9:66-75.   Back to cited text no. 6      
7.Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron cell death and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U.S.A 2002;99:2258-63.   Back to cited text no. 7      
8.Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (Lond) 2001;412:641-7.   Back to cited text no. 8      
9.Faden AI. Neuroprotection and traumatic brain injury: Theoretical option or realistic proposition. Curr Opin Neurol 2002;15:707-12.   Back to cited text no. 9  [PUBMED]  [FULLTEXT]  
10.Feeney DM, Boyeson MG, Linn RT, Murray HM, Dail WG. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res 1981;211:67-77.   Back to cited text no. 10      
11.Golarai G, Greenwood AC, Feeney DM, Connor JA. Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci 2001;21:8523-37.   Back to cited text no. 11      
12.Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U.S.A 2002;99: 9450-5.   Back to cited text no. 12      
13.Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003;64:557-69.   Back to cited text no. 13  [PUBMED]  [FULLTEXT]  
14.Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-40.   Back to cited text no. 14      
15.Stefanis L. Caspase-dependent and -independent neuronal death: Two distinct pathways to neuronal injury. Neuroscientist 2005;11:50-62.   Back to cited text no. 15  [PUBMED]  [FULLTEXT]  
16.Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 2005;57:481-7.   Back to cited text no. 16  [PUBMED]  [FULLTEXT]  
17.Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, Faden AI. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 2004;24:1119-32.   Back to cited text no. 17  [PUBMED]  [FULLTEXT]  
18.Liu CL, Siesjo BK, Hu BR. Pathogenesis of hippocampal neuronal death after hypoxia-ischemia changes during brain development. Neuroscience 2004;127:113-23.   Back to cited text no. 18      
19.Ohlsson M, Havton LA. Complement activation after lumbosacral ventral root avulsion injury. Neurosci Lett 2005;394:179-83.  Back to cited text no. 19  [PUBMED]  [FULLTEXT]  
20.Sun Y, Zhou C, Polk P, Nanda A, Zhang JH. Mechanisms of erythropoietin- induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab 2004;24:259-70.   Back to cited text no. 20      
21.Liao ZB, Zhi XG, Shi QH, He ZH. Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 2008;15:140-9.   Back to cited text no. 21  [PUBMED]  [FULLTEXT]  
22.Wei L, Ying DJ, Cui L, Langsdorf J, Yu SP. Necrosis, cell death and hybrid death in the cortex and thalamus after barrel cortex ischemia in rats. Brain Res 2004;1022:54-61.   Back to cited text no. 22  [PUBMED]  [FULLTEXT]  
23.Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal cell death and inflammation in a rodent model of experimental closed head injury. Faseb J 2005;12:1701-3.   Back to cited text no. 23      
24.Chang YS, Mu D, Wendland M, Sheldon RA, Vexler ZS, McQuillen PS, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005;58:106-11.   Back to cited text no. 24      
25.Chen S, Pickard JD, Harris NG. Time course of cellular pathology after controlled cortical impact injury. Exp Neurol 2003;182:87-102.   Back to cited text no. 25  [PUBMED]  [FULLTEXT]  
26.Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003;138:1107-18.   Back to cited text no. 26  [PUBMED]  [FULLTEXT]  
27.Casarsa C, de Luigi A, Pausa M, de Simoni MG, Tedesco F. Intracerebroventricular injection of terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 2003;33:1260-70.   Back to cited text no. 27  [PUBMED]  [FULLTEXT]  
28.Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003;23:955-60.   Back to cited text no. 28  [PUBMED]  [FULLTEXT]  
29.Kyrkanides S, O9Banion MK, Whiteley PE, Daeschner JC, Olschowka JA. Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. J Neuroimmunol 2001;119:268-77.   Back to cited text no. 29      
30.Rancan M, Morganti-Kossmann MC, Barnum SR, Saft S, Schmidt OI, Ertel W, et al. Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. J Cereb Blood Flow Metab 2003;23:1070-4.   Back to cited text no. 30      
31.Cole DS, Hughes TR, Gasque P, Morgan BP. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol Immunol 2006;43:1953-64.  Back to cited text no. 31  [PUBMED]  [FULLTEXT]  
32.Gaetz M. The neurophysiology of brain injury. Clin Neurophysiol 2004;115:4-18.   Back to cited text no. 32  [PUBMED]  [FULLTEXT]  
33.Eldadah BA, Faden AI. Caspase pathways, neuronal cell death, and CNS injury. J Neurotrauma 2000;17:811-29.   Back to cited text no. 33  [PUBMED]  [FULLTEXT]  
34.Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 2004;14:215-22.   Back to cited text no. 34  [PUBMED]  [FULLTEXT]  
35.Wong J, Hoe NW, Zhiwei F, Ng I. Cell death and traumatic brain injury. Neurocrit Care 2005;3:177-82.   Back to cited text no. 35  [PUBMED]  [FULLTEXT]  
36.Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H, Trentz O, et al. Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. J Neuroimmunol 2000;109:164-72.   Back to cited text no. 36      
37.Pillay NS, Kellaway LA, Kotwal GJ. Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model. Ann N Y Acad Sci 2005;1056:450-61.   Back to cited text no. 37  [PUBMED]  [FULLTEXT]  
38.Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha Me, et al. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol 2006;199:454-64.   Back to cited text no. 38      
39.Stahel PF, Barnum SR. The role of the complement system in CNS inflammatory diseases. Expert Rev Clin Immunol 2006;2:445-56.   Back to cited text no. 39      
40.Holers VM, Thurman JM. The alternative pathway of complement in disease: Opportunities for therapeutic targeting. Mol Immunol 2004;41:147-52.   Back to cited text no. 40  [PUBMED]  [FULLTEXT]  
41.Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003;170:1517-23.   Back to cited text no. 41  [PUBMED]  [FULLTEXT]  
42.Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005;67:524-30.   Back to cited text no. 42  [PUBMED]  [FULLTEXT]  
43.Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-10.   Back to cited text no. 43      
44.Williams S, Raghupathi R, MacKinnon MA, McIntosh TK, Saatman KE, Graham DI. i0 n situ DNA fragmentation occurs in white matter up to 12 months after head injury in man. Acta Neuropathol 2001;102:581-90.   Back to cited text no. 44  [PUBMED]  [FULLTEXT]  
45.Marciano PG, Brettschneider J, Manduchi E, Davis JE, Eastman S, Raghupathi R, et al. Neuron-specific mRNA complexity responses during hippocampal cell death after traumatic brain injury. J Neurosci 2004;24:2866-76.   Back to cited text no. 45      
46.Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, et al. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005;280:36342-54.   Back to cited text no. 46  [PUBMED]  [FULLTEXT]  
47.Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement- deficient mice. J Immunol 2000;165:5867-73.   Back to cited text no. 47  [PUBMED]  [FULLTEXT]  
48.Felderhoff-Mueser U, Sifringer M, Pesditschek S, Kuckuck H, Moysich A, Bittigau P, et al. Pathways leading to apoptotic neurodegeneration following trauma to the developing brain. Neurobiol Dis 2002;11:231-45.  Back to cited text no. 48  [PUBMED]  [FULLTEXT]  


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

This article has been cited by
1 Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?
Dominique Lerouet, Catherine Marchand-Leroux, Valérie C. Besson
Fundamental & Clinical Pharmacology. 2021; 35(3): 524
[Pubmed] | [DOI]
2 microRNA-128 enhances neuroprotective effects of dexmedetomidine on neonatal mice with hypoxic-ischemic brain damage by targeting WNT1
Hua Fang, Hua-Feng Li, Miao Yang, Ru-Rong Wang, Quan-Yun Wang, Peng-Cheng Zheng, Fang-Xiang Zhang, Jian-Ping Zhang
Biomedicine & Pharmacotherapy. 2019; 113: 108671
[Pubmed] | [DOI]
3 Effect of Erythropoietin and Stem Cells on Traumatic Brain Injury
Melek Tunc Ata,Günfer Turgut,Metin Akbulut,Ali Kocyigit,Aysun Karabulut,Hande Senol,Sebahat Turgut
World Neurosurgery. 2016; 89: 355
[Pubmed] | [DOI]
4 Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy
Helen M. Bramlett,W. Dalton Dietrich,C. Edward Dixon,Deborah A. Shear,Kara E. Schmid,Stefania Mondello,Kevin K.W. Wang,Ronald L. Hayes,John T. Povlishock,Frank C. Tortella,Patrick M. Kochanek
Journal of Neurotrauma. 2016; 33(6): 538
[Pubmed] | [DOI]
5 Anti-edema effects of rhEpo in experimental traumatic brain injury
Rodolfo Gatto,Mihir Chauhan,Neelima Chauhan
Restorative Neurology and Neuroscience. 2015; 33(6): 927
[Pubmed] | [DOI]
6 Endothelial Nitric Oxide Synthase Mediates the Cerebrovascular Effects of Erythropoietin in Traumatic Brain Injury
Jovany Cruz Navarro,Shibu Pillai,Lucido L. Ponce,Mai Van,Jerry Clay Goodman,Claudia S. Robertson
Frontiers in Immunology. 2014; 5
[Pubmed] | [DOI]
7 Erythropoietin Improved Cognitive Function and Decreased Hippocampal Caspase Activity in Rat Pups after Traumatic Brain Injury
Michelle E. Schober,Daniela F. Requena,Benjamin Block,Lizeth J. Davis,Christopher Rodesch,T. Charles Casper,Sandra E. Juul,Raymond P. Kesner,Robert H. Lane
Journal of Neurotrauma. 2014; 31(4): 358
[Pubmed] | [DOI]
8 Pharmacotherapy of Traumatic Brain Injury: State of the Science and the Road Forward: Report of the Department of Defense Neurotrauma Pharmacology Workgroup
Ramon Diaz-Arrastia,Patrick M. Kochanek,Peter Bergold,Kimbra Kenney,Christine E. Marx,Col. Jamie B. Grimes,LTC Yince Loh,LTC Gina E. Adam,Devon Oskvig,Kenneth C. Curley,Col. Wanda Salzer
Journal of Neurotrauma. 2014; 31(2): 135
[Pubmed] | [DOI]
9 Selection of reference genes for quantitative real-time PCR evaluation of chronic erythropoietin treatment effect on the SH-SY5Y and PC12 cells
Klemen Španinger,Arthur J. Sytkowski,Nataša Debeljak
Central European Journal of Chemistry. 2013; 11(3): 348
[Pubmed] | [DOI]
10 Selection of reference genes for quantitative real-time PCR evaluation of chronic erythropoietin treatment effect on the SH-SY5Y and PC12 cells
Å paninger, K. and Sytkowski, A.J. and Debeljak, N.
Central European Journal of Chemistry. 2013; 11(3): 348-357
11 A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury
McConeghy, K.W. and Hatton, J. and Hughes, L. and Cook, A.M.
CNS Drugs. 2012; 26(7): 613-636
12 Hemorrhagic progression of a contusion after traumatic brain injury: A review
Kurland, D. and Hong, C. and Aarabi, B. and Gerzanich, V. and Simard, J.M.
Journal of Neurotrauma. 2012; 29(1): 19-31
13 Hemorrhagic Progression of a Contusion after Traumatic Brain Injury: A Review
David Kurland,Caron Hong,Bizhan Aarabi,Volodymyr Gerzanich,J. Marc Simard
Journal of Neurotrauma. 2012; 29(1): 19
[Pubmed] | [DOI]
14 Recombinant human erythropoietin and nervous diseases
Meng, W. and Gu, B.
Chinese Pharmacological Bulletin. 2011; 27(12): 1640-1643
15 Effects of erythropoietin on the expression of tumor necrosis factor-alpha and Bax after facial nerve axotomy in rats
Zhang, W., Shengyu, L., Yu, Z., Bi, M., Sun, B.
Neural Regeneration Research. 2011; 6(6): 444-449
16 Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research
Derya Sargin,Heidi Friedrichs,Ahmed El-Kordi,Hannelore Ehrenreich
Best Practice & Research Clinical Anaesthesiology. 2010; 24(4): 573
[Pubmed] | [DOI]
17 Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury
Neelima B. Chauhan,Rodolfo Gatto
Brain Research. 2010; 1360: 177
[Pubmed] | [DOI]
18 Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury
Chauhan, N.B. and Gatto, R.
Brain Research. 2010; 1360: 177-192
19 Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research
Sargin, D., Friedrichs, H., El-Kordi, A., Ehrenreich, H.
Best Practice and Research: Clinical Anaesthesiology. 2010; 24(4): 573-594
20 Erythropoietin in traumatic brain injury: The "golden bullet" on the horizon?
Stahel, P.F., Flierl, M.A.
Neurology India. 2009; 57(6): 693-694


Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow